Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
BioMarin Pharmaceutical ( (BMRN) ) just unveiled an announcement.
On January 29, 2026, BioMarin Pharmaceutical Inc. priced a private offering of $850 million in 5.500% senior unsecured notes due 2034, with closing expected around February 12, 2026, and concurrently completed syndication of a new $2 billion senior secured term loan B facility alongside an $800 million term loan A facility and a $600 million senior secured revolving credit facility, all arranged in connection with its pending acquisition of Amicus Therapeutics. BioMarin plans to use the note proceeds, together with borrowings under the new term facilities and cash on hand, to fund the Amicus acquisition and related fees, with the note proceeds held in escrow until the deal closes and subject to mandatory redemption if the transaction is not completed by December 19, 2026, a financing structure that significantly increases the company’s leverage but secures the capital needed to execute a major expansion of its rare-disease portfolio and operational scale.
The most recent analyst rating on (BMRN) stock is a Buy with a $62.00 price target. To see the full list of analyst forecasts on BioMarin Pharmaceutical stock, see the BMRN Stock Forecast page.
Spark’s Take on BMRN Stock
According to Spark, TipRanks’ AI Analyst, BMRN is a Outperform.
The score is driven primarily by strong financial performance (rapid revenue growth, high margins, solid cash generation, and low leverage). It is tempered by weaker technical momentum (below key moving averages with slightly negative MACD) and event-driven uncertainty from the debt-financed Amicus acquisition and a discontinued pipeline program, while valuation remains moderate and the latest earnings call guidance was supportive despite notable one-time and strategic headwinds.
To see Spark’s full report on BMRN stock, click here.
More about BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc., based in San Rafael, California, is a global biotechnology company focused on rare diseases and genetically defined conditions. Founded in 1997, it has eight commercial therapies and a broad clinical and preclinical pipeline, aiming to develop category-defining medicines that leverage genetic science to address significant unmet medical needs.
Average Trading Volume: 2,747,665
Technical Sentiment Signal: Sell
Current Market Cap: $10.92B
Learn more about BMRN stock on TipRanks’ Stock Analysis page.